ライブ
Endpoints NewsPost-Hoc Live: Are the China hawks winning?FierceBiotechFor biopharma manufacturing at speed and scale, the future is flexibleFierceBiotechDefinium’s LSD formula produces ‘best data ever seen’ in a pivotal depression trial, CEO saysFierceBiotechHelmed by Sanofi vet, Bionyara emerges with $165M and three licensed I&I assetsEndpoints NewsRegenxbio to resubmit Hunter syndrome gene therapy without new studyEndpoints NewsDefinium reports Phase 3 hit for LSD drug in severe form of depressionEndpoints NewsAbbVie makes $10.9B move for Apogee's long-acting I&I drug candidatesEndpoints NewsA Sanofi alum looks to take on the TL1A field with $165M for BionyraBioPharma DiveBionyra brings in $165M for next-generation immune drugsEndpoints NewsSanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reinsFierceBiotechSanofi's R&D chief Ashrafian to hit the exit as new CEO seeks to fix stuttering pipeline with Roche alumEndpoints NewsNura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration

アーカイブ

最新 古い順
合計 13642
ページ 101 / 758
検索 --